Effect of PeakATP on Mood, Reaction Time and Cognition

NCT05100589 | Completed

• 1 other identifier: STUDY00003272
• Study Type: interventional
• Target: 35
• Locations: 1 country
• Sites: 1

Brief Summary

Oral ATP disodium (adenosine 5'- triphosphate disodium) is a commercially available product available alone and as a constituent in a number of sports supplements that is purported to maintain ATP levels and improve performance during high-intensity exercise. Acute deficits in cognitive performance have also been reported in both young adults and children following high-intensity exercise; however, the effects of supplemental ATP on cognitive performance has not been studied. Goals:

1. 1.To investigate the effect of ATP supplementation versus. placebo on mood, reaction time and cognitive performance before and after an acute bout of fatiguing exercise.
2. 2.To investigate the effect of ATP supplementation versus. placebo on anaerobic performance.

Conditions

Cognitive Change; Mood

Keywords

Adenosine Triphosphate

Outcome Measures

Primary Outcomes (16)

• Mood

  Assessed via administration of the POMS Questionnaire. 58 words or phrases are presented in a Likert format questionnaire reflecting how the subject feels at the time of completing the questionnaire. Scores range from 0 (Not at all) to 4 (Extremely). Tension, depression, anger, vigor, fatigue, confusion and total mood disturbance (TMD) will be measured.

  Pre (0)

• Mood

  Assessed via administration of the POMS Questionnaire. 58 words or phrases are presented in a Likert format questionnaire reflecting how the subject feels at the time of completing the questionnaire. Scores range from 0 (Not at all) to 4 (Extremely). Tension, depression, anger, vigor, fatigue, confusion and total mood disturbance (TMD) will be measured.

  Immediately post (IP)

• Mood

  Assessed via administration of the POMS Questionnaire. 58 words or phrases are presented in a Likert format questionnaire reflecting how the subject feels at the time of completing the questionnaire. Scores range from 0 (Not at all) to 4 (Extremely). Tension, depression, anger, vigor, fatigue, confusion and total mood disturbance (TMD) will be measured.

  60-minutes post (60P)

• Reaction Time

  Assessed using the Dynavision D2 visuomotor training device. Subjects are required to recognize and respond as fast as possible to random and sequentially appearing stimuli across the Dynavision apparatus target field. Mode A test - The participant will be instructed to successfully identify and strike as many stimuli as possible within 60 seconds with both hands. The number of hits and average reaction time per hit will be assessed. Mode B test - The participant will be instructed to successfully identify and strike as many stimuli as possible within 60 seconds with both hands. Additionally, the participant will be required to verbally recite a random 5-digit number that presents on the center screen (t-scope) of the D2. The 5-digit number is presented a total of 11 times throughout the 60-second test, remains for 0.75 seconds and will be randomly generated. The number of hits, misses and the average reaction time per hit will be assessed.

  Pre (0)

• Reaction Time

  Assessed using the Dynavision D2 visuomotor training device. Subjects are required to recognize and respond as fast as possible to random and sequentially appearing stimuli across the Dynavision apparatus target field. Mode A test - The participant will be instructed to successfully identify and strike as many stimuli as possible within 60 seconds with both hands. The number of hits and average reaction time per hit will be assessed. Mode B test - The participant will be instructed to successfully identify and strike as many stimuli as possible within 60 seconds with both hands. Additionally, the participant will be required to verbally recite a random 5-digit number that presents on the center screen (t-scope) of the D2. The 5-digit number is presented a total of 11 times throughout the 60-second test, remains for 0.75 seconds and will be randomly generated. The number of hits, misses and the average reaction time per hit will be assessed.

  Immediately post (IP)

• Reaction Time

  Assessed using the Dynavision D2 visuomotor training device. Subjects are required to recognize and respond as fast as possible to random and sequentially appearing stimuli across the Dynavision apparatus target field. Mode A test - The participant will be instructed to successfully identify and strike as many stimuli as possible within 60 seconds with both hands. The number of hits and average reaction time per hit will be assessed. Mode B test - The participant will be instructed to successfully identify and strike as many stimuli as possible within 60 seconds with both hands. Additionally, the participant will be required to verbally recite a random 5-digit number that presents on the center screen (t-scope) of the D2. The 5-digit number is presented a total of 11 times throughout the 60-second test, remains for 0.75 seconds and will be randomly generated. The number of hits, misses and the average reaction time per hit will be assessed.

  60-minutes post (60P)

• Multiple Object Tracking (MOT)

  Multiple object Tracking (MOT) speed will be assessed via the completion of a CORE assessment using Neurotracker MOT software. The Neurotracker MOT assessment requires participants to track four targets among eight spheres projected within a cube space. The spheres follow a linear trajectory in space, with deviations in trajectory occurring in response to collisions between balls and with the walls of the cube. The CORE assessment includes 20 trials and lasts approx. 6 minutes and challenges attention, visual information processing speed and working memory. The MOT speed threshold, defined as the speed at which the participant correctly identifies all target balls 50% of the time (i.e., the point at which their performance neither improves nor deteriorates) will be determined.

  Pre (0)

• Multiple Object Tracking (MOT)

  Multiple object Tracking (MOT) speed will be assessed via the completion of a CORE assessment using Neurotracker MOT software. The Neurotracker MOT assessment requires participants to track four targets among eight spheres projected within a cube space. The spheres follow a linear trajectory in space, with deviations in trajectory occurring in response to collisions between balls and with the walls of the cube. The CORE assessment includes 20 trials and lasts approx. 6 minutes and challenges attention, visual information processing speed and working memory. The MOT speed threshold, defined as the speed at which the participant correctly identifies all target balls 50% of the time (i.e., the point at which their performance neither improves nor deteriorates) will be determined.

  Immediately post (IP)

• Multiple Object Tracking (MOT)

  Multiple object Tracking (MOT) speed will be assessed via the completion of a CORE assessment using Neurotracker MOT software. The Neurotracker MOT assessment requires participants to track four targets among eight spheres projected within a cube space. The spheres follow a linear trajectory in space, with deviations in trajectory occurring in response to collisions between balls and with the walls of the cube. The CORE assessment includes 20 trials and lasts approx. 6 minutes and challenges attention, visual information processing speed and working memory. The MOT speed threshold, defined as the speed at which the participant correctly identifies all target balls 50% of the time (i.e., the point at which their performance neither improves nor deteriorates) will be determined.

  60-minutes post (60P)

• Symptoms checklist

  Monitor frequency and severity of subjective symptoms related to a broad spectrum of conditions. The participant is presented with 21 symptoms. The participant is required to rate each symptom (e.g. fatigue, headache, Nausea, numbness/tingling etc. on a scale from 0 (Not Present) to 6 (Severe). Assessed as part of the ANAM.

  Pre (0)

• Symptoms checklist

  Monitor frequency and severity of subjective symptoms related to a broad spectrum of conditions. The participant is presented with 21 symptoms. The participant is required to rate each symptom (e.g. fatigue, headache, Nausea, numbness/tingling etc. on a scale from 0 (Not Present) to 6 (Severe). Assessed as part of the ANAM.

  Immediately post (IP)

• Sleepiness Scale

  The subject is presented with seven different statements of alertness/sleepiness, ranging from "Feeling very alert, wide awake, and energetic" to "Very sleepy and cannot stay awake much longer." The participant is instructed to select the statement that best matches their current state.

  60-minutes post (60P)

• Cognition

  Response scores from each of seven cognitive assessments administered as part of a battery of tests via Automated Neuropsychological Assessment Metrics (ANAM) computer software. Tests include: 1. Simple reaction time 2. Code Substitution 3. Procedural Reaction Time 4. Mathematical processing 5. Matching to sample 6. Code substitution Delayed 7. Simple reaction time repeat

  Pre (0)

• Cognition

  Response scores from each of seven cognitive assessments administered as part of a battery of tests via Automated Neuropsychological Assessment Metrics (ANAM) computer software. Tests include: 1. Simple reaction time 2. Code Substitution 3. Procedural Reaction Time 4. Mathematical processing 5. Matching to sample 6. Code substitution Delayed 7. Simple reaction time repeat

  Immediately post (IP)

• Cognition

  Response scores from each of seven cognitive assessments administered as part of a battery of tests via Automated Neuropsychological Assessment Metrics (ANAM) computer software. Tests include: 1. Simple reaction time 2. Code Substitution 3. Procedural Reaction Time 4. Mathematical processing 5. Matching to sample 6. Code substitution Delayed 7. Simple reaction time repeat

  60-minutes post (60P)

• Anaerobic performance

  Subjects will complete 60 seconds of unloaded cycling at 90 rpm before immediately completing a 3-minute all-out test on a cycle ergometer. Resistance during the test will be set as a function of pedaling rate using a scaling factor based on the power output at a set cadence (70 rpm) being equal to 50% of the difference between the power output at gas exchange threshold (GET) and peak power output assessed during the VO2peak test. End power (mean power during last 30 seconds of 3-minute test), anaerobic working capacity (work above end power), peak power, mean power, time to peak power, fatigue slope (W/sec), rate of fatigue (%), and total work (joules) will be calculated

  During 3-minute test

Study Arms (2)

PeakATP

EXPERIMENTAL

PeakATP formula dissolved in 8 ounces water, taken 30 minutes before breakfast on an empty stomach, or within 30 minutes of waking.

Dietary Supplement: PeakATP

Placebo

PLACEBO COMPARATOR

Placebo formula (same as experimental with no PeakATP) dissolved in 8 ounces water, taken 30 minutes before breakfast on an empty stomach, or within 30 minutes of waking.

Dietary Supplement: Placebo

Interventions

PeakATP DIETARY_SUPPLEMENT

Powder - 400mg Peak ATP, maltodextrin, silica-colloidal anhydrous, citric acid anhydrous, sucralose, guar gum

PeakATP

Placebo DIETARY_SUPPLEMENT

Powder - maltodextrin, silica-colloidal anhydrous, citric acid anhydrous, sucralose, guar gum

Placebo

Eligibility Criteria

• Age: 18 Years - 40 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy, and ready for physical activity as determined by physical activity readiness questionnaire (PAR-Q+) and medical history questionnaire (MHQ)
• Participants will be required to be recreationally-active (defined according to the American College of Sports Medicine (ACSM) standards of at least 150 minutes exercise per week)
• Participants must currently not be taking and be willing to abstain from creatine or beta-alanine supplementation or be willing to complete a 4-week wash-out period prior to enrolling if taking creatine or beta-alanine and be willing to abstain from supplementing with wither for the duration of the study. This will be verbally confirmed at the beginning of each visit.
• Participant understands the study procedures and signs forms providing informed consent to participate in the study.

You may not qualify if:

• Individual does not provide consent to participate in this study.
• Inability to perform physical exercise (determined by MHQ and PAR Q+). That is Answering "Yes" to any question on the PAR-Q +, or having a pre-existing condition such as musculoskeletal injury, back pain, chronic pain etc. that the investigative team perceives will prevent a participant from safely completing the protocol.
• Not currently participating in at least 150 minutes of physical activity per week.
• Currently taking any performance-enhancing drug (determined from health and activity questionnaire)
• Currently taking a nutritional supplement known to improve anerobic performance that requires a wash-out period (e.g., creatine, beta-alanine) and are not willing to undergo a 4-week wash-out period prior to participating.
• Regularly taking any type of prescription or over-the-counter medication, or having any chronic illnesses, which require medical care
• Current known pregnancy

Sponsors & Collaborators

• University of Central Florida: lead

Study Sites (1)

Kinesiology Research Labs

Orlando, Florida, 32816, United States

Location

Related Publications (10)

• Du F, Zhu XH, Zhang Y, Friedman M, Zhang N, Ugurbil K, Chen W. Tightly coupled brain activity and cerebral ATP metabolic rate. Proc Natl Acad Sci U S A. 2008 Apr 29;105(17):6409-14. doi: 10.1073/pnas.0710766105. Epub 2008 Apr 28.

  PMID: 18443293 BACKGROUND

• Owen L, Sunram-Lea SI. Metabolic agents that enhance ATP can improve cognitive functioning: a review of the evidence for glucose, oxygen, pyruvate, creatine, and L-carnitine. Nutrients. 2011 Aug;3(8):735-55. doi: 10.3390/nu3080735. Epub 2011 Aug 10.

  PMID: 22254121 BACKGROUND

• Arts IC, Coolen EJ, Bours MJ, Huyghebaert N, Stuart MA, Bast A, Dagnelie PC. Adenosine 5'-triphosphate (ATP) supplements are not orally bioavailable: a randomized, placebo-controlled cross-over trial in healthy humans. J Int Soc Sports Nutr. 2012 Apr 17;9(1):16. doi: 10.1186/1550-2783-9-16.

  PMID: 22510240 RESULT

• Coolen EJ, Arts IC, Bekers O, Vervaet C, Bast A, Dagnelie PC. Oral bioavailability of ATP after prolonged administration. Br J Nutr. 2011 Feb;105(3):357-66. doi: 10.1017/S0007114510003570. Epub 2010 Dec 6.

  PMID: 21129239 RESULT

• Purpura M, Rathmacher JA, Sharp MH, Lowery RP, Shields KA, Partl JM, Wilson JM, Jager R. Oral Adenosine-5'-triphosphate (ATP) Administration Increases Postexercise ATP Levels, Muscle Excitability, and Athletic Performance Following a Repeated Sprint Bout. J Am Coll Nutr. 2017 Mar-Apr;36(3):177-183. doi: 10.1080/07315724.2016.1246989. Epub 2017 Jan 12.

  PMID: 28080323 RESULT

• Rathmacher JA, Fuller JC Jr, Baier SM, Abumrad NN, Angus HF, Sharp RL. Adenosine-5'-triphosphate (ATP) supplementation improves low peak muscle torque and torque fatigue during repeated high intensity exercise sets. J Int Soc Sports Nutr. 2012 Oct 9;9(1):48. doi: 10.1186/1550-2783-9-48.

  PMID: 23046855 RESULT

• Wilson JM, Joy JM, Lowery RP, Roberts MD, Lockwood CM, Manninen AH, Fuller JC, De Souza EO, Baier SM, Wilson SM, Rathmacher JA. Effects of oral adenosine-5'-triphosphate supplementation on athletic performance, skeletal muscle hypertrophy and recovery in resistance-trained men. Nutr Metab (Lond). 2013 Sep 22;10(1):57. doi: 10.1186/1743-7075-10-57.

  PMID: 24330670 RESULT

• de Freitas MC, Ricci-Vitor AL, Freire RV, Caperuto EC, Vanderlei LCM, Lira FS, Rossi FE. Oral adenosine 5'-triphosphate supplementation improved hemodynamic and autonomic parameters after exercise in hypertensive women. J Exerc Rehabil. 2018 Aug 24;14(4):671-679. doi: 10.12965/jer.1836256.128. eCollection 2018 Aug.

  PMID: 30276192 RESULT

• Sun S, Loprinzi PD, Guan H, Zou L, Kong Z, Hu Y, Shi Q, Nie J. The Effects of High-Intensity Interval Exercise and Hypoxia on Cognition in Sedentary Young Adults. Medicina (Kaunas). 2019 Feb 10;55(2):43. doi: 10.3390/medicina55020043.

  PMID: 30744172 RESULT

• Samuel RD, Zavdy O, Levav M, Reuveny R, Katz U, Dubnov-Raz G. The Effects of Maximal Intensity Exercise on Cognitive Performance in Children. J Hum Kinet. 2017 Jun 22;57:85-96. doi: 10.1515/hukin-2017-0050. eCollection 2017 Jun.

  PMID: 28713461 RESULT

Study Officials

• Adam J Wells, PhD

  University of Central Florida

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: OTHER
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Professor of Kinesiology

Study Record Dates

• First Submitted: October 7, 2021
• First Posted: October 29, 2021
• Study Start: October 6, 2021
• Primary Completion: April 19, 2022
• Study Completion: April 19, 2022
• Last Updated: August 8, 2022

Record last verified: 2022-08

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)